Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Income Statement
Earnings Waterfall
Crinetics Pharmaceuticals Inc
Revenue
|
2m
USD
|
Operating Expenses
|
-250.1m
USD
|
Operating Income
|
-248.2m
USD
|
Other Expenses
|
12.7m
USD
|
Net Income
|
-235.5m
USD
|
Income Statement
Crinetics Pharmaceuticals Inc
Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||||||
Revenue |
2
N/A
|
2
+19%
|
2
-7%
|
2
-4%
|
2
+11%
|
2
-3%
|
2
-28%
|
2
-2%
|
1
-28%
|
1
-24%
|
1
N/A
|
0
-57%
|
0
-82%
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
4
+290%
|
5
+10%
|
5
+10%
|
5
-7%
|
4
-9%
|
5
+13%
|
5
-2%
|
4
-15%
|
2
-51%
|
|
Operating Income | |||||||||||||||||||||||||||
Operating Expenses |
(11)
|
(14)
|
(18)
|
(24)
|
(31)
|
(36)
|
(43)
|
(50)
|
(55)
|
(62)
|
(66)
|
(69)
|
(75)
|
(80)
|
(89)
|
(99)
|
(109)
|
(123)
|
(140)
|
(156)
|
(173)
|
(186)
|
(197)
|
(212)
|
(227)
|
(250)
|
|
Selling, General & Administrative |
(2)
|
(3)
|
(3)
|
(5)
|
(7)
|
(9)
|
(11)
|
(13)
|
(14)
|
(14)
|
(16)
|
(16)
|
(18)
|
(19)
|
(21)
|
(22)
|
(25)
|
(28)
|
(33)
|
(38)
|
(42)
|
(46)
|
(49)
|
(52)
|
(58)
|
(67)
|
|
Research & Development |
(9)
|
(12)
|
(15)
|
(19)
|
(24)
|
(27)
|
(32)
|
(37)
|
(42)
|
(48)
|
(50)
|
(52)
|
(57)
|
(61)
|
(69)
|
(76)
|
(84)
|
(95)
|
(107)
|
(118)
|
(130)
|
(140)
|
(148)
|
(160)
|
(169)
|
(183)
|
|
Operating Income |
(9)
N/A
|
(12)
-32%
|
(16)
-34%
|
(22)
-35%
|
(29)
-32%
|
(33)
-16%
|
(41)
-23%
|
(48)
-18%
|
(54)
-12%
|
(62)
-14%
|
(65)
-6%
|
(68)
-5%
|
(75)
-10%
|
(80)
-7%
|
(89)
-11%
|
(99)
-10%
|
(108)
-9%
|
(119)
-10%
|
(136)
-14%
|
(151)
-12%
|
(168)
-11%
|
(182)
-8%
|
(192)
-5%
|
(208)
-8%
|
(223)
-7%
|
(248)
-11%
|
|
Pre-Tax Income | |||||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
1
|
2
|
3
|
4
|
4
|
3
|
3
|
2
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
33
|
35
|
30
|
31
|
36
|
36
|
|
Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(28)
|
(28)
|
(22)
|
(22)
|
(23)
|
(17)
|
|
Pre-Tax Income |
(9)
N/A
|
(12)
-31%
|
(16)
-33%
|
(21)
-33%
|
(27)
-28%
|
(31)
-13%
|
(38)
-22%
|
(44)
-18%
|
(50)
-14%
|
(59)
-17%
|
(63)
-7%
|
(67)
-6%
|
(74)
-11%
|
(79)
-8%
|
(89)
-12%
|
(98)
-11%
|
(108)
-9%
|
(118)
-10%
|
(135)
-14%
|
(149)
-10%
|
(163)
-10%
|
(175)
-8%
|
(184)
-5%
|
(198)
-8%
|
(209)
-5%
|
(230)
-10%
|
|
Net Income | |||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(9)
|
(12)
|
(16)
|
(21)
|
(27)
|
(31)
|
(38)
|
(44)
|
(50)
|
(59)
|
(63)
|
(67)
|
(74)
|
(79)
|
(89)
|
(98)
|
(108)
|
(118)
|
(135)
|
(149)
|
(163)
|
(175)
|
(184)
|
(198)
|
(209)
|
(230)
|
|
Equity Earnings Affiliates |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
(1)
|
(5)
|
(6)
|
|
Net Income (Common) |
(9)
N/A
|
(12)
-31%
|
(16)
-33%
|
(21)
-33%
|
(27)
-28%
|
(31)
-13%
|
(38)
-22%
|
(44)
-18%
|
(50)
-14%
|
(59)
-17%
|
(63)
-7%
|
(67)
-6%
|
(74)
-11%
|
(79)
-8%
|
(89)
-12%
|
(98)
-11%
|
(108)
-9%
|
(119)
-11%
|
(136)
-14%
|
(150)
-10%
|
(164)
-9%
|
(175)
-7%
|
(184)
-5%
|
(199)
-8%
|
(215)
-8%
|
(235)
-10%
|
|
EPS (Diluted) |
-0.42
N/A
|
-0.54
-29%
|
-0.66
-22%
|
-0.87
-32%
|
-1.12
-29%
|
-1.26
-13%
|
-1.54
-22%
|
-1.82
-18%
|
-2.09
-15%
|
-2.39
-14%
|
-2
+16%
|
-2.02
-1%
|
-2.42
-20%
|
-2.4
+1%
|
-2.4
N/A
|
-2.57
-7%
|
-2.8
-9%
|
-2.5
+11%
|
-2.58
-3%
|
-2.78
-8%
|
-3.15
-13%
|
-3.25
-3%
|
-3.38
-4%
|
-3.51
-4%
|
-3.69
-5%
|
-3.25
+12%
|